On April 8, 2013, the nine grams of MDMA to be used in our upcoming Canadian study of MDMA-assisted psychotherapy for PTSD were exported from Switzerland to Canada. The Canadian pharmacist worked for more than 2½ years to make the security adjustments to the pharmacy required by Health Canada for the import permit. MAPS’ efforts to design the protocol, receive all necessary approvals, and conduct the study began in 2007. Once the MDMA arrives at the study pharmacy after clearing customs, we will submit a series of minor protocol amendments to Health Canada and to the Canadian Institutional Review Board. Once the amendments are approved, which could take several weeks, we will begin screening and treating subjects.
Co-Principal Investigator Andrew Feldmár will give an update on training future psychedelic therapists at Psychedelic Science 2013, after U.S. Embassy finally granted him permission to enter the country after banning him for writing about psychedelic experiences he had 40 years ago.